For the roughly 300 million people living with COPD worldwide, preventing acute exacerbations — the episodes that accelerate lung function decline and drive hospitalization — remains stubbornly difficult even with optimized inhaled therapy. A novel biologic targeting a newly appreciated inflammatory mechanism could shift that calculus, and the scale of the evidence being assembled is unusually ambitious.
The LUNA programme consists of four Phase III randomized, double-blind, placebo-controlled trials enrolling a combined total exceeding 3,700 participants with symptomatic COPD and documented exacerbation histories. The therapeutic candidate is tozorakimab, a monoclonal antibody engineered to block both the reduced (IL-33red) and oxidised (IL-33ox) isoforms of interleukin-33 — a distinction that matters because prior anti-IL-33 approaches have not uniformly addressed both redox states, which may explain inconsistent trial results in this space. OBERON and TITANIA each randomize participants to tozorakimab 300 mg every four or eight weeks versus placebo over 52 weeks; MIRANDA uses a more frequent every-two-week dosing schedule in roughly 1,450 participants; and the PROSPERO extension study follows completers for up to an additional 52 weeks, including re-randomization of former placebo recipients. Primary endpoints across OBERON, TITANIA, and MIRANDA focus on annualised moderate-to-severe exacerbation rates, with PROSPERO targeting severe exacerbations — and all primary analyses are pre-specified first in former smokers before current smokers.
The dual-isoform inhibition strategy is scientifically meaningful. IL-33 is an alarmin released during epithelial injury and oxidative stress — conditions endemic to the COPD airway — and its two redox forms appear to drive both type-2 and non-type-2 inflammation. Earlier biologics in COPD targeting type-2 pathways (dupilumab, mepolizumab) showed benefit mainly in eosinophil-high subgroups, leaving the broader population underserved. Tozorakimab's mechanism could theoretically extend benefit to a wider COPD phenotype, but that remains to be proven. Limitations here are structural: this publication describes trial design, not outcomes, so efficacy conclusions await full readout. The pre-specification of the former-smoker subgroup as the primary analysis population is an intriguing epidemiological choice that will be worth scrutinizing when results emerge.